Osteomark

Osteomark®

Metabolism A proprietary urine test for measuring bone loss, quantifying cross-linked N-telopeptides–NTx, which are degradation products of bone resorption and are unique biochemical markers specific for the type I collagen–found in bone. See Hormone replacement therapy, N-telopeptides, Osteoporosis.
References in periodicals archive ?
A group of researchers compared the Pyrilinks-D test to other bone resorption tests like Osteomark and CrossLaps.
sALP was determined by the Tandem-MP Ostase Immunoenzymetric Assay (Beckman Coulter) (10) and NTx by the Osteomark NTx Assay (Ostex International) (11).
Forward-looking statements in this release involve a number of risks and uncertainties including, but not limited to, product demand, pricing, market acceptance of the Osteomark tests, changing economic conditions, the actions of competitors, the effect of the Company's accounting policies, meeting regulatory requirements for the Company's new products and other risk factors detailed in the Company's SEC filings.
Forward looking statements in this release involve a number of risks and uncertainties including, but not limited to, product demand, pricing, market acceptance of the Osteomark tests, changing economic conditions, the actions of competitors, the effect of the Company's accounting policies, meeting regulatory requirements for the Company's new products and other risk factors detailed in the Company's SEC filings.
Sales of the Osteomark NTx Urine and Serum kits and the Point-of-Care device increased over the comparable quarter in 2002 and sales were particularly strong for the Company's serum kits.
Thomas Bologna, Ostex' Chairman, President and Chief Executive Officer, stated, "The acquisition of the manufacturing and expanded use rights for the Osteomark Point-of-Care device represents a key strategic opportunity for our Company.
The Company's lead product, the OSTEOMARK NTx test, now available in multiple formats, incorporates breakthrough and patented technology for the management and prevention of osteoporosis.
Our results for the first quarter were compounded by delayed shipments of the Osteomark NTx Urine kits in late March.
Forward looking statements in this release involve a number of risks and uncertainties including, but not limited to, product demand, pricing, market acceptance of the Osteomark test, changing economic conditions, the actions of competitors, the effect of the Company's accounting policies, meeting regulatory and CLIA waiver requirements for the Company's new products and other risk factors detailed in the Company's SEC filings.
The Company also recorded a $75,000 tax expense in the third quarter of 2002 for Japanese withholding taxes related to the $750,000 in payments received from Mochida Pharmaceutical in March and August 2002 per the Serum Osteomark License Agreement.